Shots:
- The CHMP has recommended Beyonttra to treat wild-type or variant transthyretin amyloidosis cardiomyopathy (ATTR-CM) in adults, expected to launch in H1’25
- Opinion was based on a P-III (ATTRibute-CM) study of Beyonttra (BID, oral) vs PBO in ATTR-CM patients. It achieved its 1EP, showing a 42% reduced composite ACM & recurrent CVH events & a 50% reduced cumulative frequency of CVH events at 30mos.
- Acoramidis (TTR stabilizer) was developed by BridgeBio & Bayer. BridgeBio has US marketing rights for the drug, while Bayer holds them in the EU
Ref: BridgeBio & Bayer | Image: BridgeBio & Bayer| Press Release
Related News:- Gilead Receives CHMP’s Positive Opinion of Seladelpar to Treat Primary Biliary Cholangitis (PBC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
